Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
about
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksFunctional imaging for prostate cancer: therapeutic implications.Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments.Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?Macrophage cathepsin K promotes prostate tumor progression in bone.Docetaxel-based combination therapy for castration-resistant prostate cancer.Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.Development of Bone Targeting Drugs.Production, quality control, and determination of human absorbed dose of no carrier added 177 Lu-risedronate for bone pain palliation therapy.[Systemic treatment of metastatic prostate cancer].Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model.Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer.Synthesis and pharmacological evaluation of 99mTc-labeled imidazolyl-containing diphosphonic acid as a novel bone imaging agent.An easy and effective method for synthesis and radiolabelling of risedronate as a model for bone imaging.Evaluation of antitumor activity and cardiac toxicity of a bone-targeted ph-sensitive liposomal formulation in a bone metastasis tumor model in mice.
P2860
Q34960686-92C1F89A-0D56-484F-B483-BA8A06F6DA84Q36128629-C6152C4E-C8A3-41F5-8447-993A2C428B16Q36970516-6407B261-CBD3-41CE-A020-80EB7413B1F4Q37428071-C1C92896-C74E-486F-837C-7741CC6B2820Q37554550-587B39F3-A889-4465-8276-8A12B2A20E5DQ37721016-DCF00F07-7717-4B26-B37C-7281A751A3F1Q37724378-7876A9C9-DF8A-43EC-9954-E2D043F3568AQ38667546-CD380CB0-7CF1-466A-A544-C2BFDAB89320Q39175247-5E444029-5E09-4290-AAEF-D7229799AE55Q39290649-E8E76FC0-7020-44F2-8954-EFB36C3291D9Q39789556-F05FEF0A-97FB-493C-9AF4-B5A6E8D9F313Q42382543-47BC3CE0-1B46-427F-9F44-0AB576666818Q45280534-153BB3E2-9FB3-4AB3-94CF-185616CD9B63Q46205142-8635EA88-746D-4CA1-B2B5-CFE73A9F1FDAQ46807603-1620C4A9-1716-40D4-BC5A-DD0A1595BDFCQ53400480-F8BDE8B3-6BA2-4055-8B2A-AD3AE4629B8D
P2860
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@ast
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@en
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@nl
type
label
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@ast
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@en
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@nl
prefLabel
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@ast
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@en
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@nl
P2860
P1433
P1476
Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
@en
P2093
Matthew R Smith
P2860
P304
P356
10.1016/J.UROLONC.2007.11.004
P577
2008-07-01T00:00:00Z